Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab Ozogamicin + Rituximab Alternating with R-GEMOX in R/R DLBCL
NCT01562990Phase 2Completed
- Sponsor
- LYSARC
- Start
- Dec 2012
- Primary completion
- Aug 2014
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of inotuzumab ozogamicin in diffuse large B-cell lymphoma (DLBCL), sponsored by LYSARC. Started Dec 2012; status: completed.
02
Drugs
inotuzumab ozogamicin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01562990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01562990.